Ouverture de l’appel à solutions AReNA est heureux d’annoncer le lancement du premier appel à solutions de la CELLULE. Cette nouvelle approche d’accompagnement et de financement des innovations permettra d’accélérer le développement de technologies hautement prometteuses ayant le potentiel de résoudre certaines problématiques industrielles d’importance limitant actuellement le développement et l’utilisation des thérapies ARN. Les…
Montréal, le 11 juin 2024 – Le CQDM est fier d’annoncer la création du Réseau de développement et de production de thérapies ARN qui offrira des services de biofabrication en thérapies ARN aux chercheurs académiques et industriels. Mené par l’Institut de recherches cliniques de Montréal (IRCM), l’Université McGill et l’Université Sherbrooke, ce Réseau s’inscrit parmi…
Cette nouvelle initiative sera mise en œuvre avec l’appui et l’expertise de Axelys Montréal, le 6 juin 2024 – Le CQDM est heureux d’annoncer le lancement d’une nouvelle initiative ambitieuse visant à stimuler l’innovation et l’entrepreneuriat dans la filière de l’ARN thérapeutique au Québec. Menée par Axelys, en collaboration avec plusieurs partenaires, cette initiative s’inscrit…
San Diego, California – June 3rd, 2024 – CQDM, in collaboration with Axelys, Montréal InVivo and RNA Québec is proud to introduce AReNA, the new Québec’s RNA Hub. Unveiled at the BIO conference in San Diego, in the presence of the Minister for the Economy, the Minister responsible for the Fight Against Racism, and the…
San Diego, California – June 3rd, 2024 – CQDM, in collaboration with Axelys, Fonds de recherche du Québec, Génome Québec, and Médicament Québec, announces the launch of the CELLULE, a new model to support and finance the development of promising technologies based on the use of RNA. This announcement is to be made at the…
CQDM. We share.Canadian health science companies are invited to submit an expression of interest to pitch in person to global investors at the 2024 OBIO® Investment Summit (OIS) in Toronto on February 14–16, 2024.Selected Canadian health science companies seeking their next raise and demonstrating high growth potential and readiness for investment will pitch virtually to…
$50 million to support biotech companies. In order to ensure the continuity of the financing chain for the life sciences sector, the government of Quebec announces the renewal of BioMed Propulsion. This will be allocated an envelope of $50 million to support biotechnology and medical technology companies which have already reached the early stages of their…
AI and drug development.An interesting conference discussing artificial intelligence and drug development. Come hear Yoshua Bengio discuss AI advances in the field at the next adMare BioInnovations ‘Global Leaders’ series event.-Thursday, October 5, at noon (EST)-Online webinar-RSVP: https://www.admarebio.com/en/events-details/detail/admare-global-leader-series-featuring-yoshua-bengio/45424
Congratulations Université Laval. A large-scale international collaborative study lead by Professor Jacques Simard from Université Laval and Professor Douglas Easton at the University of Cambridge, UK, has identified new genes associated with breast cancer that could eventually be included in tests to identify women at increased risk. The study found evidence for at least four…
Laval, Canada – (BUSINESSWIRE) – April 13, 2023 – BIOQuébec, CQDM, Fonds de solidarité FTQ and adMare BioInnovations, co-organizers of Sweet Biopharma Day, are pleased to announce that Epitopea is the winner of the 2023 edition. Sixteen Canadian startup companies (“Sweet 16”) selected by representatives from global pharma companies, made an elevator pitch in front of…